Novartis' Pelacarsen misses primary endpoint, shares slide 3.3%
Novartis disclosed that its late‑stage Pelacarsen trial lowered Lipoprotein(a) but did not reduce heart attacks, strokes or cardiovascular deaths, prompting a 3.3% drop in the stock and a 12% fall in Ionis shares.
Novartis announced that its pivotal Pelacarsen trial did not lower the incidence of major cardiovascular events, even though the drug achieved a substantial reduction in Lipoprotein(a) levels. The news sent Novartis shares down 3.3% in early Monday trade and pulled Ionis Pharmaceuticals shares about 12% in after‑hours U.S. trading.
Trial outcomes
The trial, which lasted more than six years and enrolled over 8,000 patients, was designed to test whether monthly injections of Pelacarsen could cut the rate of heart attacks, strokes and cardiovascular deaths – the study’s primary composite endpoint. According to the Handelsblatt report, the primary endpoint was not met. The drug, however, succeeded in lowering patients’ Lipoprotein(a) concentrations, a biomarker linked to cardiovascular risk.
Novartis medical head Shreeram Aradhye said the results were “not what the company had hoped for,” underscoring the disappointment in a trial that had been closely watched by investors and clinicians alike.
Market reaction
Novartis disclosed the trial results late on Friday, 4 September 2026. The following Monday, 7 September 2026, the stock fell 3.3% in early trade, as reported by Handelsblatt. Ionis Pharmaceuticals, which co‑develops Pelacarsen, saw its shares tumble roughly 12% in after‑hours U.S. trading on the same day.
| Company | Share decline | Period | Source |
|---|---|---|---|
| Novartis | 3.3 % | Early Monday trade, 7 Sep 2026 | Handelsblatt |
| Ionis Pharmaceuticals | 12 % | After‑hours U.S. trade, 7 Sep 2026 | Handelsblatt |
Implications for Novartis and Ionis
Novartis (ticker NVS, listed on the NYSE) is headquartered in Basel, Switzerland, and employs roughly 119,418 people according to its most recent SEC filing. The company’s chief executive is Vasant Narasimhan. While the Lipoprotein(a) reduction confirms the drug’s biological activity, the failure to improve hard cardiovascular outcomes means the product will not advance toward regulatory approval in its current form.
Ionis Pharmaceuticals (ticker IONS, Nasdaq) is based in Carlsbad, United States. The share price drop reflects investor concerns that the partnership’s flagship asset may not generate the anticipated revenue stream. Ionis’s latest 10‑Q filing (ended 30 June 2026) shows a net loss of $207.2 million and total assets of $2.99 billion, underscoring the financial pressure of a missed late‑stage trial.
Background and next steps
The Pelacarsen programme has been a collaborative effort between Novartis and Ionis, targeting patients with elevated Lipoprotein(a), a known independent risk factor for atherosclerotic disease. The trial’s primary endpoint – a composite of major adverse cardiovascular events – was predefined as a statistically significant reduction versus placebo. The negative result does not preclude further analysis of secondary endpoints or sub‑group signals, but any regulatory filing would need to demonstrate a clear clinical benefit.
Both companies have not disclosed a revised development timeline. The Handelsblatt article notes that the results were “not what the company had hoped for,” but does not specify whether additional studies are planned or whether the partnership will pursue alternative dosing strategies.
Investors should watch for a formal Novartis press release or regulatory filing that may clarify the company’s strategic response. Until then, the share‑price moves remain the most immediate market signal of the trial’s impact.
In summary, the Pelacarsen trial confirms the drug’s ability to lower Lipoprotein(a) but fails to translate that biomarker change into fewer heart attacks, strokes or cardiovascular deaths. The miss triggered a modest decline in Novartis stock and a sharper sell‑off in Ionis, reflecting the high expectations that had been placed on the therapy.